Oncology
Non-Small Cell Lung Cancer
Frontline and Emerging Immunotherapies in Non–Small Cell Lung Cancer
The integration of ICIs targeting the PD-1/PD-L1 axis has transformed the treatment paradigm for patients whose cancers lack actionable driver alterations. Next-generation immunotherapeutic strategies aim to overcome resistance, improve efficacy across PD-L1 levels, and improve durability for patients with non–small cell lung cancer (NSCLC).
For metastatic NSCLC without actionable driver mutations, platinum-based chemotherapy with or without an ICI remains standard first-line practice. Similar approaches are also often used for patients whose tumors harbor biologically plausible targets that lack US Food and Drug Administration (FDA)–approved therapies or available clinical trials. There are no head-to-head comparisons among the individual FDA-approved ICIs. The KEYNOTE-189 trial established pembrolizumab plus pemetrexed and a platinum-based drug as a standard of care for the first-line treatment of metastatic nonsquamous NSCLC without EGFR or ALK alterations, and many clinicians therefore favor pembrolizumab-based regimens.
Dual checkpoint blockade is used less often but can be considered for high-risk patients in whom PD-1 monotherapy plus chemotherapy may be less effective, including selected younger, fit patients with heavy tobacco use and KRAS-mutant disease with STK11 or KEAP1 co-mutations. However, immune-related toxicity is substantially more frequent with combination checkpoint inhibition.
Regarding future directions, investigations of ICI-based combination strategies are expected to continue. I believe that VEGF targeting continues to have a meaningful role in lung cancer. Multiple dual-targeting constructs are under investigation, including ivonescimab (an investigational bsAb targeting PD-1 and VEGFA) and pumitamig (an investigational bsAb targeting PD-L1 and VEGFA). The ROSETTA Lung-02 trial of pumitamig plus chemotherapy has shown promising early activity; however, we need phase 3 data confirming a durable benefit before this strategy can be adopted in practice.
Both Dr Florez’s practice and mine skew toward younger patients with oncogene-driven disease. As a result, I infrequently use dual checkpoint blockade regimens such as CheckMate 9LA or POSEIDON, which combine a PD-1 or PD-L1 inhibitor with a CTLA-4 inhibitor, with or without chemotherapy. When I do consider them, it is typically in PD-L1–negative tumors with concurrent KEAP1 or STK11 mutations—genomic features that may predict attenuated benefit from KEYNOTE-189–style chemoimmunotherapy. However, for the majority of patients without a targetable driver alteration, my default remains chemotherapy plus PD-1 or PD-L1 blockade.
The HARMONi-6 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, tested a different intensification strategy: ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC. Ivonescimab improved overall survival, including in PD-L1–negative disease. Several other HARMONi trials, including trials in patients with nonsquamous histology, are being conducted, and reporting over the next year is anticipated. Whether bispecific PD-1/VEGF agents will supplant PD-1 inhibitors, and in which patients, remain open questions. We will need the larger later-stage global studies, for sure, but it will be interesting to see what is going to happen with those different bsAbs.
As my colleagues noted, platinum-based chemotherapy with or without an ICI remains standard first-line practice. I routinely discuss PD-L1 expression and explain that a higher PD-L1 Tumor Proportion Score (TPS) correlates with greater benefit from ICI monotherapy. For patients with a PD-L1 TPS of greater than or equal to 50%, I generally recommend avoiding chemotherapy, instead opting for ICI monotherapy (unless the patient is highly symptomatic). For patients with a PD-L1 TPS of less than 50%, I typically favor chemoimmunotherapy.
No ICI has been shown to be superior to another in this setting, as Dr Florez mentioned. The same is true of perioperative chemoimmunotherapy: KEYNOTE-671, AEGEAN, and CheckMate 77T have produced broadly similar results. I regard these regimens as interchangeable; differences in trial design are modest, and choice usually comes down to access and clinician familiarity.
There is interest in developing novel immunotherapeutic combinations, including ADCs in combination with immunotherapy, and there is also interest in bsAbs. Additional checkpoints such as TIGIT, LAG-3, and TIM-3 have also been explored, but a consistent clinical benefit has not been demonstrated. Some of the most important factors in this area, in my view, are patient selection and the further development of biomarkers so that the most appropriate regimen can be matched to the individual patient.
Cascone T, Awad MM, Spicer JD, et al; CheckMate 77T Investigators. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756-1769. doi:10.1056/NEJMoa2311926
Chen Z, Yang F, Luo Y, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: overall survival results of the phase 3 HARMONi-6 trial. J Clin Oncol. 2026;44(suppl 17):LBA4. doi:10.1200/JCO.2026.44.17_suppl.LBA4
Dong C, Wang X. Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy. Antib Ther. 2026;9(2):191-200. doi:10.1093/abt/tbag016
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005
Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992-1998. doi:10.1200/JCO.22.01989
Heymach JV, Harpole D, Mitsudomi T, et al; AEGEAN Investigators. Perioperative durvalumab for resectable non–small-cell lung cancer. N Engl J Med. 2023;389(18):1672-1684. doi:10.1056/NEJMoa2304875
Johnson ML, Cho BC, Luft A, et al; POSEIDON Investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213-1227. doi:10.1200/JCO.22.00975
Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211. Published correction appears in Lancet Oncol. 2021;22(3):e92.
Peters S, Lee Y, Erman M, et al. Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 x VEGF-A bsAb) + chemotherapy in 1L NSCLC. J Clin Oncol. 2026;44(suppl 16):8513. doi:10.1200/JCO.2026.44.16_suppl.8513
Wakelee H, Liberman M, Kato T, et al; KEYNOTE-671 Investigators. Perioperative pembrolizumab for early-stage non–small-cell lung cancer. N Engl J Med. 2023;389(6):491-503. doi:10.1056/NEJMoa2302983


